These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

111 related items for PubMed ID: 12510990

  • 21. The impact of idiopathic childhood-onset growth hormone deficiency (GHD) on bone mass in subjects without adult GHD.
    Lange M, Müller J, Svendsen OL, Kastrup KW, Juul A, Feldt-Rasmussen U.
    Clin Endocrinol (Oxf); 2005 Jan; 62(1):18-23. PubMed ID: 15638865
    [Abstract] [Full Text] [Related]

  • 22. Influence of growth hormone on accretion of bone mass.
    Monson JP, Drake WM, Carroll PV, Weaver JU, Rodriguez-Arnao J, Savage MO.
    Horm Res; 2002 Jan; 58 Suppl 1():52-6. PubMed ID: 12373015
    [Abstract] [Full Text] [Related]

  • 23. The role of growth hormone in glucocorticoid-induced osteoporosis.
    Lombardi G, Colarusso S, Di Somma C, Guerra E, Tauchmanova L, Colao A.
    J Endocrinol Invest; 2008 Jul; 31(7 Suppl):38-42. PubMed ID: 18791350
    [Abstract] [Full Text] [Related]

  • 24. Bone mass development and bone metabolism in juvenile idiopathic arthritis: treatment with growth hormone for 4 years.
    Bechtold S, Ripperger P, Bonfig W, Schmidt H, Bitterling H, Häfner R, Schwarz HP.
    J Rheumatol; 2004 Jul; 31(7):1407-12. PubMed ID: 15229964
    [Abstract] [Full Text] [Related]

  • 25. Effects of growth hormone treatment in juvenile idiopathic arthritis: bone and body composition.
    Bechtold S, Dalla Pozza R, Schwarz HP, Simon D.
    Horm Res; 2009 Nov; 72 Suppl 1():60-4. PubMed ID: 19940498
    [Abstract] [Full Text] [Related]

  • 26. Effect of short-term therapy with recombinant human growth hormone (GH) on metabolic parameters and preclinical atherosclerotic markers in hypopituitary patients with growth hormone deficiency.
    Benedini S, Dalle Carbonare L, Albiger N, Scanarini M, Bilora F, Petrobelli F, Giannini S, Mantero F, Scaroni C.
    Horm Metab Res; 2006 Jan; 38(1):16-21. PubMed ID: 16477535
    [Abstract] [Full Text] [Related]

  • 27. Final height and growth hormone secretion after completion of growth hormone therapy in patients with idiopathic growth hormone deficiency and with abnormalities of the hypothalamic-pituitary region.
    Hilczer M, Smyczynska J, Stawerska R, Lewinski A.
    Neuro Endocrinol Lett; 2005 Feb; 26(1):19-24. PubMed ID: 15726014
    [Abstract] [Full Text] [Related]

  • 28. The effect of cessation of growth hormone (GH) therapy on bone mineral accretion in GH-deficient adolescents at the completion of linear growth.
    Cowell CT, Högler W.
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4506; author reply 4506-7. PubMed ID: 12970332
    [No Abstract] [Full Text] [Related]

  • 29. Indications for GH replacement in adolescents and young adults.
    Monson JP.
    J Endocrinol Invest; 2005 Sep; 28(5 Suppl):52-5. PubMed ID: 16114277
    [Abstract] [Full Text] [Related]

  • 30. The effect of growth hormone treatment on bone mineral density in prepubertal girls with Turner syndrome: a multicentre prospective clinical trial.
    Aycan Z, Cetinkaya E, Darendeliler F, Vidinlisan S, Bas F, Bideci A, Demirel F, Darcan S, Buyukgebiz A, Yildiz M, Berberoglu M, Bundak R.
    Clin Endocrinol (Oxf); 2008 May; 68(5):769-72. PubMed ID: 17980015
    [Abstract] [Full Text] [Related]

  • 31. Metabolic effects of stopping growth hormone: body composition and energy expenditure.
    Gregory JW.
    J Pediatr Endocrinol Metab; 2002 Dec; 15 Suppl 5():1347-50. PubMed ID: 12510989
    [Abstract] [Full Text] [Related]

  • 32. Long-term effects of growth hormone (GH) treatment on body composition and bone mineral density in short children born small-for-gestational-age: six-year follow-up of a randomized controlled GH trial.
    Willemsen RH, Arends NJ, Bakker-van Waarde WM, Jansen M, van Mil EG, Mulder J, Odink RJ, Reeser M, Rongen-Westerlaken C, Stokvis-Brantsma WH, Waelkens JJ, Hokken-Koelega AC.
    Clin Endocrinol (Oxf); 2007 Oct; 67(4):485-92. PubMed ID: 17561977
    [Abstract] [Full Text] [Related]

  • 33. Use of GnRH agonists in GH-deficient patients: arguments for and against. The case for GnRH agonists in GH-deficient patients.
    Lee PA.
    Pediatr Endocrinol Rev; 2008 Feb; 5 Suppl 2():744-9. PubMed ID: 18317446
    [Abstract] [Full Text] [Related]

  • 34. The role for growth hormone in linking arthritis, osteoporosis, and body composition.
    Tauchmanova L, Di Somma C, Rusciano A, Lombardi G, Colao A.
    J Endocrinol Invest; 2007 Feb; 30(6 Suppl):35-41. PubMed ID: 17721072
    [Abstract] [Full Text] [Related]

  • 35. Short stature and decreased insulin-like growth factor I (IGF-I)/growth hormone (GH)-ratio in an adult GH-deficient patient pointing to additional partial GH insensitivity due to a R179C mutation of the growth hormone receptor.
    Meyer S, Ipek M, Keth A, Minnemann T, von Mach MA, Weise A, Ittner JR, Nawroth PP, Plöckinger U, Stalla GK, Tuschy U, Weber MM, Kann PH, German KIMS Board, German KIMS Pharmacogenetics Study Group.
    Growth Horm IGF Res; 2007 Aug; 17(4):307-14. PubMed ID: 17462934
    [Abstract] [Full Text] [Related]

  • 36. Cardiac dimension and function in patients with childhood onset growth hormone deficiency, before and after growth hormone retreatment in adult age.
    Feinberg MS, Scheinowitz M, Laron Z.
    Am Heart J; 2003 Mar; 145(3):549-53. PubMed ID: 12660681
    [Abstract] [Full Text] [Related]

  • 37. GH treatment and its effect on bone mineral density, bone maturation and growth in short children born small for gestational age: 3-year results of a randomized, controlled GH trial.
    Arends NJ, Boonstra VH, Mulder PG, Odink RJ, Stokvis-Brantsma WH, Rongen-Westerlaken C, Mulder JC, Delemarre-Van de Waal H, Reeser HM, Jansen M, Waelkens JJ, Hokken-Koelega AC.
    Clin Endocrinol (Oxf); 2003 Dec; 59(6):779-87. PubMed ID: 14974922
    [Abstract] [Full Text] [Related]

  • 38. Baseline characteristics and the effects of two years of growth hormone replacement therapy in adults with growth hormone deficiency previously treated for Cushing's disease.
    Johannsson G, Sunnerhagen KS, Svensson J.
    Clin Endocrinol (Oxf); 2004 May; 60(5):550-9. PubMed ID: 15104557
    [Abstract] [Full Text] [Related]

  • 39. Growth hormone replacement therapy (GHRT) in children and adolescents: skeletal impact.
    Mukherjee A, Shalet SM.
    Med Pediatr Oncol; 2003 Sep; 41(3):235-42. PubMed ID: 12868125
    [Abstract] [Full Text] [Related]

  • 40. Growth hormone (GH) secretion and pituitary size in children with short stature. Efficacy of GH therapy in GH-deficient children, depending on the pituitary size.
    Hilczer M, Szalecki M, Smyczynska J, Stawerska R, Kaniewska D, Lewinski A.
    Neuro Endocrinol Lett; 2005 Oct; 26(5):447-52. PubMed ID: 16264418
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.